Volume 29, Issue 5, 2020
DOI: 10.24205/03276716.2020.1091
Clinical Therapeutic Effects of Clarityne Combined with Singulair On Cough Variant Asthma in Children and Influence on Eosinophils in Sputum
Abstract
Objective: To assess the clinical therapeutic effects of Clarityne combined with Singulair on cough variant asthma in children and the influence on eosinophils in sputum.
Methods: Seventy children with cough variant asthma admitted to our hospital from January 2018 to December 2019 were randomly divided into two groups (n=35) using a random number table. Control group was treated with Clarityne, while observation group was treated with Clarityne + Singulair. The clinical efficacy, disappearance time of symptoms and signs, serum inflammatory factors, eosinophils, immunoglobulins, pulmonary ventilation function indices and incidence rate of adverse reactions were compared.
Results: The total clinical effective rate was higher in observation group than that in control group (97.14% vs. 82.86%, P<0.05). The disappearance time of symptoms such as cough and wheezing was shorter in observation group than that in control group (P<0.05), and the disappearance time of pulmonary wheezing sound was shorter in observation group than that in control group (P<0.05). The levels of interleukin-2 (IL-2), IL-4 and C-reactive protein declined in both groups after treatment in comparison with those before treatment, and they were lower in observation group than those in control group after treatment (P<0.05). The concentrations of eosinophils in sputum and serum dropped in both groups after treatment in contrast with those before treatment (P<0.05), and they were lower in observation group than those in control group after treatment (P<0.05). In comparison with those before treatment, the levels of Immunoglobulin G (IgG), IgA and IgM rose in both groups after treatment, and they were higher in observation group than those in control group (P<0.05). Compared with those before treatment, the forced expiratory volume in one second (FEV1) and FEV1/forced vital capacity increased in both groups after treatment, and they were higher in observation group than those in control group (P<0.05). There was no significant difference in the incidence rate of adverse reactions between observation group and control group (5.71% vs. 2.86%, P>0.05).
Conclusion: Clarityne combined with Singulair has good efficacy in the treatment of cough variant asthma in children. It can effectively relieve the symptoms and signs of children, reduce their inflammatory response, regulate their immune function, and help improve their pulmonary ventilation function. The combination of the two drugs leads to few adverse reactions, which is safe and reliable
Keywords
cough variant asthma; Clarityne; Singulair; eosinophils